Recce share price jumps 15% on positive data

The Recce share price jumped nearly 15% higher today on news out of the company before being sold off to a 6% gain at the time of writing.

| More on:
increasing bar graph created from medical tablets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price traded nearly 15% higher this morning after the company announced positive oral data.

What new data has Recce released?

Recce Pharmaceuticals released an announcement earlier today which highlighted positive oral data for the company's new antibiotic RECCE 435. The data relates to an independent efficacy study that assessed the oral dose-dependent efficacy of RECCE 435 in an animal model. According to the announcement, the data showed positive efficacy against Helicobacter plylori (H. pylori) in rats treated with RECCE 435.

H. pylori is a Gram-negative and antibiotic-resistant bacteria that infects the lining of the stomach and upper intestine. The bacteria was recently added by the United States Food and Drug Administration as a pathogen that has the potential to pose a threat to public health and has an unmet medical need.

The study involved treating 3 groups with varying doses of RECCE 435, with dose-dependent efficacy reported at all doses which resulted in significant reduction in bacterial load. The company's management noted that the new data is encouraging and endorses further study into synthetic antibiotics in the treatment of deadly infections. As a result, Recce Pharmaceuticals is in discussion with world leading H. pylori experts to assess a potential commercial pathway.

What does Recce do?

Recce Pharmaceuticals is an Australian based biopharmaceutical company that aims at developing and commercialising new classes of synthetic anti-infectives to treat antibiotic resistant superbugs and emerging viral pathogens. The company's antibiotics are unique as their potency does not diminish with repeated use, which is a failure of existing antibiotics used to treat resistant superbugs.

RECCE 327 is the company's lead candidate which has been developed for the treatment of blood infections and sepsis that results from E.coli and S. aureus bacteria. In addition to the aforementioned RECCE 435, RECCE 529 is another candidate from Recce Pharamceuticals that is designed as an antiviral compound.  

Earlier last month, Reece Pharmaceuticals announced that the company had entered an agreement with US-based precision medicine company, Path BioAnalytics, for the study of its RECCE 327 and RECCE 529 antibiotics against SARS-CoV-2, which is the strain of coronavirus that causes COVID-19. In addition, the company noted that its candidate RECCE 327 has been accepted into the SARS-CoV-2 screening program between the CSIRO and Doherty Institute.

The Recce share price

Following its initial surge, the Recce share price has been sold off and is currently trading at $1.255 which is a 6.4% increase for the day. This came after the share price hit an intra-day high of $1.355 immediately following the announcement. The Recce share price is 269% up in year-to-date trading.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Woman with a scared look has hands on her face.
Broker Notes

Bapcor shares fell more than 30% yesterday. Should investors buy in the dip?

Is this a value opportunity?

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Broker Notes

Broker raises price targets on 2 ASX 200 shares to buy

Ord Minnett has just upped its 12-month share price targets on 2 buy-rated ASX 200 stocks.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why DroneShield, Gentrack, Metals X, and Northern Star shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Morgans says these ASX can rise 30% to 50%

The broker has good things to say about these shares.

Read more »

Two businessmen look out at the city from the top of a tall building.
Broker Notes

2 ASX REITs to buy in July: expert

Is it time to consider ASX REITs?

Read more »